BioMark Diagnostics (TSE:BUX) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
BioMark Diagnostics Inc. has announced that research findings on glioblastoma, a challenging brain tumor with limited treatment options, will be presented at the GPEN Conference in Copenhagen. The studies, conducted by the University of Manitoba, include innovative approaches to treatment and the evaluation of BioMark’s liquid biopsy technology for monitoring treatment response.
For further insights into TSE:BUX stock, check out TipRanks’ Stock Analysis page.